Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, summarizes the main findings of a study using bispecific T-cell engagers (BiTEs) to target chronic viral hepatitis B and hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Prof. Protzer explains that these constructs can bind the HBV surface antigen on infected hepatocytes and activate T-cells. The study showed that these BiTes had a potent anti-viral and anti-tumor activity in both cell cultures and mouse models. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.